• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DFAN14A filed by Quanterix Corporation

    4/22/25 4:30:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email
    DFAN14A 1 n4845_x14-dfan14a.htm DFAN14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    Filed by the Registrant [_]

    Filed by a party other than the Registrant [X]

    Check the appropriate box:

    [_]Preliminary Proxy Statement
    [_]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    [_]Definitive Proxy Statement
    [X]Definitive Additional Materials
    [_]Soliciting Material Pursuant to §240.14a-12

     

    QUANTERIX CORPORATION

    (Name of Registrant as Specified In Its Charter)

     

    KENT LAKE PARTNERS LP

    KENT LAKE PR LLC

    BENJAMIN NATTER

    ALEXANDER G. DICKINSON

    BRUCE FELT

    HAKAN SAKUL

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    [X]No fee required.
    [_]Fee paid previously with preliminary materials.
    [_]Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

    Kent Lake Partners LP (“Kent Lake Partners”) has filed a definitive proxy statement and accompanying GOLD proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes in connection with its opposition to proposals to be presented at a special meeting of stockholders (the “Special Meeting”) of Quanterix Corporation, a Delaware corporation (the “Company”), in connection with the Company’s agreement and plan of merger (the “Merger”) with Akoya Biosciences, Inc. Kent Lake Partners, together with the other Participants (as defined below), also intends to file a preliminary proxy statement and accompanying GOLD universal proxy card with the SEC to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of the Company (the “Annual Meeting”).

    On April 22, 2025, Kent Lake Partners issued additional slides to its Investor Presentation that was filed with the SEC on April 21, 2025, a copy of which is attached hereto as Exhibit 1 and is incorporated herein by reference.

     

    Certain Information Concerning the Participants

    Kent Lake Partners LP (“Kent Lake Partners”) has filed a definitive proxy statement and accompanying GOLD proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes in connection with its opposition to proposals to be presented at a special meeting of stockholders (the “Special Meeting”) of Quanterix Corporation, a Delaware corporation (the “Company”), in connection with the Company’s agreement and plan of merger (the “Merger”) with Akoya Biosciences, Inc. Kent Lake Partners, together with the other Participants (as defined below), also intends to file a preliminary proxy statement and accompanying GOLD universal proxy card with the SEC to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of the Company (the “Annual Meeting”).

    KENT LAKE STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

    The participants in the proxy solicitation against the Merger in connection with the Special Meeting are anticipated to be Kent Lake Partners, Kent Lake PR LLC (“Kent Lake PR”) and Benjamin Natter (collectively, the “Kent Lake Parties”). The participants in the proxy solicitation in connection with the Annual Meeting are anticipated to be the Kent Lake Parties and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the “Kent Lake Nominees” and collectively with the Kent Lake Parties, the “Participants”).

    As of the date hereof, Kent Lake Partners directly beneficially owned 3,001,000 shares of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 3,001,000 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 3,001,000 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

     

     

     

    Get the next $QTRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/10/25 4:08:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana covered exercise/tax liability with 4,395 shares, decreasing direct ownership by 5% to 81,618 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    2/6/26 6:58:51 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by President and CEO Cunningham Everett

    4 - Quanterix Corp (0001503274) (Issuer)

    1/21/26 4:15:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Cunningham Everett

    3 - Quanterix Corp (0001503274) (Issuer)

    1/21/26 4:08:59 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

    Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix's LucentAD® Complete LDT Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnostic tools to aid in the evaluation of patients with cognitive symptoms for possible AD. The multi-analy

    2/3/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling

    Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstr

    1/21/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the "Inducement Grants") were made to four employees in connection with the commencement of their employment. The Inducement Grants consist of 88,050 restricted stock units ("RSUs") representing 88,050 shares of Quanterix common stock and options to purchase ("Options") an aggregate of 125,745 shares of Quanterix common stock at an exercise price of $7.95 per share, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date

    1/16/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Quanterix with a new price target

    Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

    2/1/24 6:32:54 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

    9/25/23 9:03:48 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    SEC Filings

    View All

    SEC Form S-8 filed by Quanterix Corporation

    S-8 - Quanterix Corp (0001503274) (Filer)

    1/15/26 4:53:09 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Leadership Update, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    1/8/26 4:46:24 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by Quanterix Corporation

    S-8 - Quanterix Corp (0001503274) (Filer)

    12/22/25 4:15:56 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Financials

    Live finance-specific insights

    View All

    Quanterix Releases Financial Results for the Third Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. "During the third quarter, we delivered on our revenue expectations despite challenging market conditions," said Masoud Toloue, Chief Executive Officer of Quanterix. "Equally important, we achieved key integration milestones from our Akoya transaction — keeping us firmly on track to realize $85 million in annualized synergies and reach cash flow break-even in 2026. Together, we have built a stronger, more scalable company with the foundation to drive sustained growth,

    11/10/25 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results. Quanterix will issue a press release regarding its third quarter 2025 financial results prior to the conference call on Monday, November 10, 2025, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 3186071. Interested investors can also acces

    11/3/25 7:00:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Releases Financial Results for the Second Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market," said Masoud Toloue, CEO of Quanterix. "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market. Within the quarter, our Accelerator business reported a net i

    8/7/25 4:06:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said

    7/8/25 9:07:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    11/13/24 12:41:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Quanterix Corporation

    SC 13G - Quanterix Corp (0001503274) (Subject)

    6/27/24 2:46:59 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    2/14/24 4:57:53 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials